Drug Trial Radar · NCT07236944
Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care
Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
560
Planned (sponsor's estimate)
Start
Dec 2025
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- Uppsala UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Swedish Research Council
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if oral treatment with pivmecillinam is effective to treat febrile urinary tract infections in adult patients. Hospitalized patients who have received 2-4 days of intravenous antibiotic therapy for febrile urinary tract infections, and have responded to treatment, will be randomized to either pivmecillinam or standard treatment (other oral or intravenous antibiotics). The main question the study aims to answer is if oral follow-up with pivmecillinam is as effective as standard treatment. Patients will be evaluated for clinical response (resolution of fever and urinary tract symptoms) and microbiological response (no growth of bacteria in urine) 7 and 28 days after the end of treatment. Patients will also be asked about side effects. Some of the participants will also be examined for changes in the gut microbiome and drug exposures in blood and urine. Participants will: 1. Keep a patient diary to record antibiotic intake, body temperature, urinary tract symptoms, and suspected side effects until 7 days after end of treatment. 2. Participate in phone interviews 7 and 28 days after end of treatment to assess clinical response. 3. Provide urine samples 7 and 28 days after end of treatment to evaluate microbiological response. 4. A subgroup (60 patients) will provide fecal samples at five time-points over three months to assess antibiotic-induced changes in the gut microbiome. 5. A subgroup (30 patients) treated with to pivmecillinam will provide blood and urine samples to determine the pharmacokinetics of mecillinam during one dosing interval.
Conditions
- Febrile Urinary Tract Infection
Interventions
PivmecillinamDrug
Patients randomized to pivmecillinam will be provided with 400 mg tablets for 3 to 8 days of treatment, to be taken four times daily, resulting in a total treatment duration of 7 or 10 days (including the initial 2-4 days of intravenous treatment). The shorter treatment duration of 7 days will be used for female patients with no complicating factors (structural or functional urologic abnormalities, urinary tract catheterization, and diabetes mellitus). The longer treatment duration of 10 days will be used for all other patients.
Standard of Care (Investigator Choice)Drug
The control group will receive standard of care antibiotic treatment at the discretion of the responsible physician and according to existing treatment guidelines, with a total treatment duration of 7 to 14 days. The following antibiotics will be considered adequate. Intravenous antibiotics: 1) Penicillins; ampicillin, piperacillin/tazobactam, 2) cephalosporins; cefotaxime, cefuroxime, ceftriaxone, 3) carbapenems; ertapenem, imipenem, meropenem, 4) monobactams; aztreonam, 5) aminoglycosides; amikacin, gentamicin, tobramycin, 6) other; fosfomycin. Oral antibiotics: 1) ciprofloxacin, 2) trimethoprim-sulfamethoxazole, 3) amoxicillin or amoxicillin/clavulanic acid provided that the isolated E. coli is determined susceptible according to the EUCAST-breakpoint for systemic infections, i.e., MIC ≤ 8 mg/l, and high dosing is used (≥750 mg amoxicillin x 3 and ≥750 mg amoxicillin/125 mg clavulanic acid x 3, respectively) and 4) tebipenem (if approved by the EMA).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical response (primary endpoint).Time frame: 7 (+/-2) days after EOT
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Haukeland University Hospital
Haukeland, Norway · Not yet recruiting
Oslo University Hospital
Oslo, Norway · Not yet recruiting
Södra Älvsborg Hospital
Borås, Sweden · Not yet recruiting
Eskilstuna Hospital
Eskilstuna, Sweden · Not yet recruiting
Sahlgrenska University Hospital
Gothenburg, Sweden · Recruiting
Blekinge Hospital
Karlskrona, Sweden · Not yet recruiting
Skåne University Hospital
Lund, Sweden · Not yet recruiting
Örebro University Hospital
Örebro, Sweden · Recruiting
Karolinska University Hospital
Stockholm, Sweden · Not yet recruiting
Sundsvall Hospital
Sundsvall, Sweden · Not yet recruiting
Umeå University Hospital
Umeå, Sweden · Not yet recruiting
Uppsala University Hospital
Uppsala, Sweden · Recruiting
Central Hospital Växjö
Vaxjo, Sweden · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.